Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15392117 | 0.81 | KDM4E (0.55) | KDM4EPKMACKR3NAMPT | |
| SCHEMBL13625750 | 0.81 | KDM4E (0.55) | KDM4EPKMACKR3NAMPT | |
| SCHEMBL12723099 | 0.80 | KDM4E (0.60) | KDM4EPKMACKR3NAMPTGPR119 | |
| SCHEMBL3272146 | 0.80 | KDM4E (0.60) | KDM4EPKMACKR3NAMPTGPR119 | |
| SCHEMBL19706814 | 0.80 | KDM4E (0.60) | KDM4EPKMACKR3NAMPTGPR119 | |
| SCHEMBL13172555 | 0.78 | GPR119 (0.53) | KDM4EPKMTGFBR1GPR119STS | |
| SCHEMBL27158621 | 0.77 | KAT7 (0.56) | KDM4EPKMTGFBR1ACKR3HTR6 | |
| SCHEMBL3285436 | 0.77 | PKM (0.61) | KDM4EPKMNAMPTACACB | |
| SCHEMBL8444728 | 0.77 | KDM4E (0.58) | KDM4EPKMTGFBR1HTR6GPR119 | |
| SCHEMBL12628193 | 0.76 | KDM4E (0.51) | KDM4EPKMTGFBR1ACKR3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191333-A1 | Antibacterial agents | MRPL21, RPN2, FBL | KDM4E 4500/4885PKM 3536/4885TGFBR1 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.